daomubiji

maximized our opportunities. We will now focus on a few areas where we Tiffany 1837 tag pendant be among the best, and this starts with neurology. We have excellent R&D and commercial capabilities in neurology, and we will build from that strength. We also have expertise and some excellent programs in hemophilia and immunology and will pursue select projects in those therapeutic areas as well. We will leverage our strengths in biologics manufacturing to bring forward our own projects as well as aggressively in-license projects in our target areas. Second, as a result of these actions, Biogen Idec will be leaner, more nimble and more decisive. Importantly, the initiatives announced will save more than $300 million annually and will position Biogen Idec to accomplish great things in the future.” Becoming a Global Leader in Neurological Diseases Biogen Idec intends to expand its global leadership in MS by maximizing the potential of AVONEX(R) (interferon beta-1a) and TYSABRI(R) (natalizumab) and aggressively Tiffany Red heart lock charm and bracelet forwardits promising MS pipeline, including fampridine, BG-12, PEGylated interferon, daclizumab and anti-LINGO.The company will aggressively pursue emerging opportunities in personalized medicine for MS patients, positioning Biogen Idec to offer patients and their caregivers personalized treatment options that best match their needs.In addition, Biogen Idec will leverage its existing neurology R&D expertise to bring life-saving and life-changing therapies to patients with serious neurological diseases, such as amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, and Parkinson’s disease, where there is a Paloma’s Zellige bracelet need for new treatments. In August 2010, the company expanded its R&D efforts for ALS when it announced a new partnership with Knopp Biosciences to develop and commercialize dexpramipexole. Biogen Idec anticipates beginning a Phase 3 clinical trial with dexpramipexole in the first half of 2011. Leveraging Strengths in Biologics Biogen Idec will also employ rigorous criteria for pursuing the treatment of other select serious diseases. For example, the company will leverage its immunobiology, process development and biologics manufacturing expertise to target high-potential treatments for select disorders where there is a significant unmet need and where the drug candidate has the potential to be highly differentiated. Biogen Idec will also continue to pursue its long-acting rFactor VIII and rFactor IX programs, which have the potential to bring much-needed advances to hemophilia patients.